215 related articles for article (PubMed ID: 15738663)
1. Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds.
Yang WD; Gomes RR; Alicknavitch M; Farach-Carson MC; Carson DD
Tissue Eng; 2005; 11(1-2):76-89. PubMed ID: 15738663
[TBL] [Abstract][Full Text] [Related]
2. Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding.
Casper CL; Yang W; Farach-Carson MC; Rabolt JF
Biomacromolecules; 2007 Apr; 8(4):1116-23. PubMed ID: 17326680
[TBL] [Abstract][Full Text] [Related]
3. Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells.
Muthusamy A; Cooper CR; Gomes RR
BMC Biochem; 2010 Nov; 11():43. PubMed ID: 21047416
[TBL] [Abstract][Full Text] [Related]
4. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors.
Smith SM; West LA; Govindraj P; Zhang X; Ornitz DM; Hassell JR
Matrix Biol; 2007 Apr; 26(3):175-84. PubMed ID: 17169545
[TBL] [Abstract][Full Text] [Related]
5. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices.
Yang W; Gomes RR; Brown AJ; Burdett AR; Alicknavitch M; Farach-Carson MC; Carson DD
Tissue Eng; 2006 Jul; 12(7):2009-24. PubMed ID: 16889529
[TBL] [Abstract][Full Text] [Related]
6. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.
Whitelock JM; Murdoch AD; Iozzo RV; Underwood PA
J Biol Chem; 1996 Apr; 271(17):10079-86. PubMed ID: 8626565
[TBL] [Abstract][Full Text] [Related]
7. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin.
Brown KJ; Hendry IA; Parish CR
J Cell Biochem; 1995 May; 58(1):6-14. PubMed ID: 7543903
[TBL] [Abstract][Full Text] [Related]
8. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity.
Guillonneau X; Tassin J; Berrou E; Bryckaert M; Courtois Y; Mascarelli F
J Cell Physiol; 1996 Jan; 166(1):170-87. PubMed ID: 8557766
[TBL] [Abstract][Full Text] [Related]
9. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis.
Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J
Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core.
Mongiat M; Otto J; Oldershaw R; Ferrer F; Sato JD; Iozzo RV
J Biol Chem; 2001 Mar; 276(13):10263-71. PubMed ID: 11148217
[TBL] [Abstract][Full Text] [Related]
11. Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.
French MM; Gomes RR; Timpl R; Höök M; Czymmek K; Farach-Carson MC; Carson DD
J Bone Miner Res; 2002 Jan; 17(1):48-55. PubMed ID: 11771669
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.
Chuang CY; Lord MS; Melrose J; Rees MD; Knox SM; Freeman C; Iozzo RV; Whitelock JM
Biochemistry; 2010 Jul; 49(26):5524-32. PubMed ID: 20507176
[TBL] [Abstract][Full Text] [Related]
13. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan.
Tran PK; Tran-Lundmark K; Soininen R; Tryggvason K; Thyberg J; Hedin U
Circ Res; 2004 Mar; 94(4):550-8. PubMed ID: 14739157
[TBL] [Abstract][Full Text] [Related]
14. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells.
Dodge GR; Boesler EW; Jimenez SA
Lab Invest; 1995 Nov; 73(5):649-57. PubMed ID: 7474938
[TBL] [Abstract][Full Text] [Related]
15. Myeloperoxidase-derived oxidants selectively disrupt the protein core of the heparan sulfate proteoglycan perlecan.
Rees MD; Whitelock JM; Malle E; Chuang CY; Iozzo RV; Nilasaroya A; Davies MJ
Matrix Biol; 2010 Jan; 29(1):63-73. PubMed ID: 19788922
[TBL] [Abstract][Full Text] [Related]
16. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.
Lord MS; Chuang CY; Melrose J; Davies MJ; Iozzo RV; Whitelock JM
Matrix Biol; 2014 Apr; 35():112-22. PubMed ID: 24509440
[TBL] [Abstract][Full Text] [Related]
17. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.
Sharma B; Handler M; Eichstetter I; Whitelock JM; Nugent MA; Iozzo RV
J Clin Invest; 1998 Oct; 102(8):1599-608. PubMed ID: 9788974
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias.
Kvist AJ; Johnson AE; Mörgelin M; Gustafsson E; Bengtsson E; Lindblom K; Aszódi A; Fässler R; Sasaki T; Timpl R; Aspberg A
J Biol Chem; 2006 Nov; 281(44):33127-39. PubMed ID: 16956876
[TBL] [Abstract][Full Text] [Related]
20. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells.
Whitelock JM; Graham LD; Melrose J; Murdoch AD; Iozzo RV; Underwood PA
Matrix Biol; 1999 Apr; 18(2):163-78. PubMed ID: 10372557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
